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Abstract
Calcium-binding proteins may endow tumor cells with properties related to their malignancy and metastatic phenotype.
Chromatographic procedures and amino acid sequence analysis were used in this study to identify seven calcium-binding
proteins, annexin VI, cap g, annexin V, calmodulin, S100A11, S100B and S100A6, associated with uveal melanoma, the
primary ocular tumor of adults. This series of calcium-binding proteins was identified in both primary tumors and cell lines
of uveal melanoma. Several of the proteins were shown by immunochemical methods to be differentially expressed between
normal uveal melanocytes and malignant melanomas of the uvea. In addition, the expression of S100A6 may correlate with
the malignant properties of the tumor. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Several novel calcium-binding proteins recently
were identi¢ed in ocular tissues and their normal
functions and their involvement in neurodegenerative
diseases delineated [1]. Recoverin, for example, ap-
pears to mediate the actions of calcium during light
adaptation, perhaps by regulating the phosphoryla-
tion of the photopigment molecule, rhodopsin [2].
Aside from its role in phototransduction, the aber-
rant expression of recoverin in cancers developing
outside of the eye causes an autoimmune response
and the subsequent degeneration of photoreceptor
cells [3]. In addition to this ‘remote e¡ect’ of cancer,
calcium-binding proteins have been implicated in es-
tablishing the malignant and metastatic phenotypes
of various tumors [4^6], including uveal melanoma
[7], the most prevalent primary ocular tumor of
adults. These calcium-binding proteins have been
useful as diagnostic or prognostic indicators [8^11],
and in the future they may serve as sites for inter-
vention with drug treatment or gene therapy.
In this paper we describe a series of calcium-bind-
ing proteins associated with uveal melanoma. Their
identity and di¡erential expression in normal mela-
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nocytes and in spindle cell and epithelioid cell malig-
nant melanomas are reported. The involvement of
these proteins in determining the malignant proper-
ties of the tumor is discussed.
2. Materials and methods
2.1. Puri¢cation of calcium-binding proteins from
uveal tissues
Normal uveal melanocytes were obtained from
human donor eyes as previously described [12].
OCM-1 spindle cell and OCM-3 epithelioid cell
malignant melanomas were established in culture
from human biopsied tumors [13]. Approx. 106 of
each cell type were used for Western blots, while
approx. 108 of each were used for chromatographic
puri¢cations.
Cells were lysed in hypoosmotic bu¡er containing
EDTA, and calcium-binding proteins were puri¢ed
by a combination of phenyl-Sepharose chromatogra-
phy and RP-HPLC [14]. Brie£y, cells were resus-
pended in 50 mM HEPES bu¡er, pH 7.5, containing
100 mM NaCl and 1.0 mM EDTA and disrupted
with a glass-glass tissue grinder followed by sonica-
tion. The homogenate was centrifuged at 48 000Ug
for 20 min and the supernatant adjusted with calci-
um chloride to yield a ¢nal concentration of 2 mM.
The extract was applied to a phenyl-Sepharose col-
umn (1U2 cm) equilibrated with the same HEPES
bu¡er containing 2 mM calcium chloride. The col-
umn was washed and bound material subsequently
eluted with the same HEPES bu¡er containing 10
mM EDTA. Fractions were analyzed by SDS-
PAGE and individual proteins puri¢ed using a C4
reversed-phase column [14]. Partial or complete ami-
no acid sequence was obtained by Edman analysis
and mass spectrometry [15].
Aliquots of the initial cellular homogenates were
also used for quantifying each of the calcium-binding
proteins by Western analysis as described below.
Tumor tissue was obtained from freshly enucleated
eyes of patients diagnosed with a malignant melano-
ma of the uvea. Half of the tissue was processed for
routine pathological examination, while the remain-
der was homogenized and processed for phenyl-Se-
pharose chromatography.
2.2. Antibody production and puri¢cation
Anti-peptide antibodies to S100A111 and S100A6
were generated using synthetic peptides correspond-
ing to the nine and eight carboxy terminal amino
acids from each of the human protein sequences,
respectively. An additional C-terminal lysine residue
in each peptide was used for conjugation to Keyhole
Limpet hemocyanin. The procedures for antigen
preparation, antisera production and a⁄nity puri¢-
cation of the anti-peptide antibodies have been pub-
lished [15].
2.3. SDS-PAGE and Western blot analysis
Proteins from the phenyl-Sepharose eluates ob-
tained from cultured cells or from homogenates of
tumor tissue and aliquots from lysed cells were re-
solved on SDS-15% polyacrylamide mini-gels and
electrotransferred to Immobilon (Millipore). Western
blots were incubated sequentially with primary anti-
body (1 Wg/ml), a 1/5000 dilution of alkaline phos-
phatase conjugated anti-immunoglobulin IgG, and a
mixture of Nitroblue tetrazolium salt and 5-bromo-4-
chloro-3-indolyl-phosphate as described elsewhere
[16]. Densitometry was performed using a Hewlett-
Packard ScanJet 3c/t scanner and SigmaGel software
(Jandel Scienti¢c, San Rafael, CA).
2.4. Immuno£uorescence microscopy
Cells were plated in Nunc (Naperville, IL) culture
chamber slides and ¢xed for a total of 30 min with
4% paraformaldehyde, 5% sucrose in 0.13 M sodium
phosphate bu¡er, pH 7.4. Cells were permeabilized
by incubation for 4 min with 0.5% Triton X-100 in
PBS. After blocking with 3% BSA, 0.1% glycine,
0.1% normal goat serum in PBS, cells were incubated
sequentially with primary antibody (1 Wg/ml), biotin-
yl anti-immunoglobulin IgG (3 Wg/ml) and streptavi-
din-Texas red conjugates (1 Wg/ml) [16].
1 For nomenclature see: Scha«fer et al., Genomics 25 (1995)
638^643 and Wicki et al., Cell Calcium 20 (1996) 459^464.
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3. Materials
Antibodies were purchased from the following
vendors: mouse anti-human annexin VI antibodies
(Zymed Laboratories, San Francisco, CA); rabbit
anti-bovine annexin VI antibodies (Biodesign Inter-
national, Kennebunk, ME); rabbit anti-human an-
nexin V antibodies (Celsus Laboratories, Cincinnati,
OH); rabbit anti-bovine antibodies to S100 proteins
(Dako, Carpinteria, CA); mouse anti-bovine anti-
bodies to S100A1 and S100B (Chemicon Internation-
al, Temecular, CA); rabbit anti-bovine S100B (East
Acres Biologicals, Southbridge, MA); mouse anti-
bovine calmodulin antibodies (Upstate Biotechnol-
ogy, Lake Placid, NY); mouse anti-rabbit GAPDH
antibodies (Biogenesis, Sandown, NH). Alkaline
phosphatase conjugated anti-immunoglobulin IgG
was purchased from Sigma (St. Louis, MO). Biotinyl
conjugated anti-immunoglobulin IgG was obtained
from Vector Laboratories (Burlingame, CA). Strep-
tavidin-Texas red is a product of Amersham (Arling-
ton Heights, IL). Monoclonal antibodies speci¢c for
cap g were the generous gift of Dr. Frederick South-
wick (University of Florida, Gainesville, FL). Cell
lines OCM-1, OCM-3, and M-7 were generously pro-
vided by Dr. June Kan-Mitchell (University of Cal-
ifornia, San Diego, CA).
4. Results
4.1. Ocular tumors express a unique set of
calcium-binding proteins
Novel calcium-binding proteins (and the aberrant
expression of known calcium-binding proteins) may
be associated with the development of malignant and
metastasizing uveal melanomas in humans [7,17]. An
analysis of the calcium-binding proteins in uveal mel-
anoma, therefore, was undertaken. A cutaneous mel-
anoma cell line (M-7), normal uveal melanocytes,
and human uveal melanoma cell lines OCM-1 and
OCM-3 were used for comparative purposes. OCM-1
is comprised of spindle cells, while OCM-3 consists
primarily of epithelioid cells [13]. These two mor-
phologies relate to malignancy and mortality; epithe-
lioid cells often are associated with more malignant
tumors and 5 year survival is diminished in the case
of epithelioid or mixed cell tumors when compared
to tumors composed primarily of spindle cells
[18,19].
Extracts of M-7, OCM-1 and OCM-3 were sub-
jected to phenyl-Sepharose chromatography as pre-
viously described for retinal extracts [14]. SDS-
PAGE revealed six major protein bands in each of
the three cell lines with Mr of approx. 67 000, 39 000,
35 000, 18 000, 12 000 and 9500 (Fig. 1A). While the
protein staining patterns were similar between the
three cell lines, some di¡erences were apparent (de-
scribed later).
The phenyl-Sepharose eluate depicted in Fig. 1A
was subjected to fractionation by RP-HPLC on a C4
column [14]. The identity of each protein was deter-
mined by partial amino acid sequence analysis em-
ploying both mass spectrometry and Edman analysis.
The following proteins were identi¢ed in this man-
ner: annexin VI (67 kDa), cap g (39 kDa), annexin V
Fig. 1. Identi¢cation of the calcium-binding proteins associated
with cutaneous and ocular melanoma cell lines. Homogenates
of cell lines derived from a cutaneous melanoma (M-7), a spin-
dle cell ocular melanoma (OCM-1) and an epithelioid cell ocu-
lar melanoma (OCM-3) were extracted with EDTA. A soluble
fraction was adjusted with calcium, applied to a phenyl-Sephar-
ose column, and material that bound to the column eluted with
EDTA as described in Section 2. Aliquots of the ¢nal eluates
were subjected to SDS-polyacrylamide gel electrophoresis and
stained with Coomassie brilliant blue. The eluate from OCM-1
is depicted in panel A. Molecular mass standards were: phos-
phorylase b (94 kDa), bovine serum albumin (67 kDa), ovalbu-
min (43 kDa), carbonic anhydrase (30 kDa), soybean trypsin
inhibitor (20.1 kDa), and K-lactalbumin (14.4 kDa). An aliquot
from the phenyl-Sepharose eluate of OCM-1 depicted in panel
A was transferred to Immobilon and immunostained as de-
scribed in Section 2 with antibodies speci¢c for: annexin VI
(lane a), cap g (b), annexin V (c), calmodulin (d), S100A11 (e),
S100B (f), and S100A6 (g).
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(35 kDa), calmodulin (18 kDa ^ in the presence of
EGTA), S100A11 (12 kDa), and two co-migrating
proteins at 9.5 kDa (S100B and S100A6).
None of the protein bands depicted in Fig. 1A
were detected when the starting culture medium
was processed for phenyl-Sepharose chromatogra-
phy. Medium was also collected after harvesting
each of the cell lines, and none of the calcium-bind-
ing proteins were detected in the conditioned me-
dium (data not shown).
4.2. Some calcium-binding proteins are di¡erentially
expressed
Antibodies speci¢c for each of the calcium-binding
proteins were generated in our laboratory or ob-
tained from other sources. Fig. 1B illustrates a West-
ern blot stained with antibodies speci¢c for annexin
VI (a), cap g (b), annexin V (c), calmodulin (d),
S100A11 (e), S100B (f), and S100A6 (g).
Antibodies were used initially in Western analyses
to quantify each of the calcium-binding proteins in
cellular homogenates of cutaneous melanoma, nor-
mal uveal melanocytes, OCM-1 spindle cells and
OCM-3 epithelioid cells. As a control for loading
artifact, GAPDH was stained in the same series of
immunoblots. As an example, the annexin VI immu-
nostaining of di¡erent cellular homogenates is illus-
trated in Fig. 2. As shown in this ¢gure, annexin VI
was detected in each of the cell lines with the excep-
tion of the normal uveal melanocytes ^ lane b (top
panel). GAPDH staining demonstrated that equiva-
lent amounts of protein were present in each lane
(bottom panel). The immunostaining of each calci-
um-binding protein was conducted in at least three
independent experiments, and blots were subse-
quently scanned and the densitometric areas deter-
mined. The results of the analysis are illustrated in
Fig. 3. Normal melanocytes (UM) expressed signi¢-
cantly lower levels of each of the calcium-binding
proteins when compared to the other cell types ^
only annexin V immunoreactivity was comparable.
While present in OCM-1 and OCM-3, cap g and
S100A11 were expressed at lower levels in M-7 as
well as normal melanocytes. Finally, S100A6 was ex-
pressed at higher levels in OCM-1 and M-7, the cell
Fig. 2. Quantifying annexin VI and other calcium-binding pro-
teins. Homogenates from cutaneous melanoma cell line M-7
(lane a), normal uveal melanocytes (b), and spindle cell (c) and
epithelioid cell (d) uveal melanoma cell lines OCM-1 and
OCM-3, respectively, were resolved by SDS-polyacrylamide gel
electrophoresis, transferred to Immobilon and stained with anti-
bodies speci¢c for annexin VI. The same experiment was con-
ducted in at least triplicate for each of the antibodies depicted
in Fig. 1. GAPDH immunostaining for each of the cell lines is
shown in the lower panel.
Fig. 3. Di¡erential expression of calcium-binding proteins. Fol-
lowing the procedures outlined in the legend of Fig. 2 and Sec-
tion 2, immunoblots from at least three separate experiments
were quanti¢ed by densitometry and area integration. Values
are the mean þ S.D. UM, normal uveal melanocytes.
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lines with the shortest doubling times. This observa-
tion is consistent with previous reports that the ex-
pression of S100A6 is related to the growth of the
tumor [20].
4.3. S100B is expressed equally in spindle cell and
epithelioid cell ocular melanomas
Previous immunohistochemical studies indicated
that S100B is nearly absent in the spindle cells of
OCM-1 and signi¢cantly reduced in the epithelioid
cells of OCM-3 [17]. In our experiments, extracts
from these cell lines were resolved by SDS-PAGE
and electrotransferred to Immobilon for immunos-
taining with a series of antibodies speci¢c for S100
proteins (Fig. 4). Antibodies from Dako (speci¢c for
S100A1 and S100B; panel A), Chemicon (speci¢c for
S100A1 and S100B; panel B), and East Acres (spe-
ci¢c for S100B; panel C) stained the same 9 kDa
band. In separate experiments, S100A1 was not de-
tected. The immunostaining illustrated in Fig. 4,
therefore, re£ects the amount of S100B, which is
equivalent in the one cutaneous melanoma cell line
and the two ocular melanoma cell lines. Equivalent
amounts of GAPDH were detected in each of the
extracts (panel D).
Previous immunohistochemical techniques may
have failed to detect the relevant epitope for S100B
in para⁄n-embedded cells and biopsy tissues. There-
fore, cells were grown in culture chamber slides, ¢xed
with paraformaldehyde and processed for staining
with a series of antibodies. As seen in Fig. 5, both
uveal melanoma cell lines and M-7 stained with anti-
bodies speci¢c for S100B (East Acres), thus corrob-
orating our ¢ndings by Western analysis. The Chem-
icon antibodies used by other laboratories, however,
Fig. 4. Western blot staining of S100B in cutaneous melanoma and spindle cell and epithelioid cell ocular melanomas. Extracts from
M-7, OCM-1 and OCM-3 (left to right in each panel) were transferred to Immobilon and blots were incubated with antibodies speci¢c
for a series of S100 proteins (A), S100A1 and S100B (B), and S100B (C). Antibodies speci¢c for GAPDH (D) demonstrate equal
amounts of protein in each lane.
Fig. 5. Immunohistochemistry of S100B in cutaneous melanoma
and spindle cell and epithelioid cell ocular melanomas. M-7,
OCM-1 and OCM-3 cells were cultured in chamber slides for
1^2 days, ¢xed and processed for immunostaining with antibod-
ies speci¢c for S100B as described in Section 2. Omission of the
primary antibody resulted in no detectable staining.
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stained relatively few cells (data not shown), indicat-
ing that the S100B epitope recognized by this anti-
body is not easily accessible for immunohistochemi-
cal staining.
4.4. Cap g and S100A11 are unique regulators of the
actin cytoskeleton
In addition to their use with Western blots, anti-
bodies were employed in immunohistochemical stud-
ies. Cap g staining of OCM-1 (panel A) and OCM-3
(panel B) is shown in Fig. 6. (S100A11 immunostain-
ing was comparable; data not shown.) The three cell
lines were stained extensively in the perinuclear re-
gion as well as the remainder of their cytoplasm.
Staining extended throughout the cell processes, in-
cluding the elongated processes from spindle cell sub-
types.
While melanocytes are characterized by vimentin-
containing intermediate ¢laments that can, in con-
junction with anti-keratin and anti-S100 staining,
distinguish them from ¢broblasts and pigment epi-
thelial cells [12], their other cytoplasmic ¢laments
are not well characterized. Since cap g and
S100A11 have been associated with actin ¢laments
in other cell types, M-7, OCM-1 and OCM-3 were
grown on culture chamber slides and stained with 0.3
mM rhodamine-conjugated phalloidin in order to la-
bel F-actin. Extensive cytoplasmic labeling was ob-
served (Fig. 6C,D), similar to the immunostaining
pro¢les for cap g and S100A11.
4.5. The same calcium-binding proteins discovered in
cell lines of ocular melanoma are also detected in
primary tumors
Results from in vitro studies must be con¢rmed
using primary tissues. Ocular melanoma tumor tissue
therefore was obtained within 30 min of enucleation
and processed for phenyl-Sepharose chromatogra-
phy. Western analysis was performed using antibod-
ies to each of the calcium-binding proteins originally
identi¢ed from studies of cell lines. As shown in Fig.
7, each of the calcium-binding proteins identi¢ed in
cell lines could be detected in primary tumors. This
¢nding validates, at least in part, our contention that
cell lines are useful for the initial identi¢cation of
pertinent molecules that otherwise might be di⁄cult
to isolate and study in less abundant and less avail-
able primary tumor tissue. It was necessary in our
studies of primary tumor tissue to extend the incu-
bation period solely for anti-S100A6 staining. This
Fig. 6. Cap g and F-actin staining of OCM-1 and OCM-3. Cells were cultured and processed with antibodies speci¢c for cap g (A,B)
or 0.3 WM rhodamine-conjugated phalloidin (C,D) as described in Section 2. (A,C) OCM-1 cells ; (B,D) OCM-3 cells.
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makes sense, since S100A6 expression correlates with
tumor growth, and primary tumors do not display
rates of growth comparable to cells in culture which
are exposed to growth factors and special media.
5. Discussion
Calcium is the most ubiquitous non-degradable
second messenger known in biology. Many of its
e¡ects are mediated by calcium-binding proteins,
and their study has yielded important insights into
the normal function and pathologies associated with
a wide variety of cells. In this respect, studies of
ocular tissues have helped to characterize more com-
plex portions of the central nervous system and, in
particular, novel calcium-binding proteins with iden-
ti¢ed functions and pathologies [1] are proving rele-
vant to other tissues.
In addition to retinal degenerations caused by gene
mutations that speci¢cally e¡ect photoreceptor cells,
the expression of a calcium-binding protein, recover-
in, was demonstrated to cause photoreceptor degen-
eration as a remote e¡ect of cancer. This is not the
sole link between cancer and the expression of cal-
cium-binding proteins. The presence of certain calci-
um-binding proteins has long been used to identify
tumors [21,22]; these same proteins might be in-
volved in the cellular pathways that endow tumor
cells with special properties related to their malignant
and metastatic phenotypes. S100A6, for example, is a
cell cycle-related gene [23,24] that is overexpressed in
several human tumors [10,11,20]. Cap g regulates
actin polymerization in response to changes in the
concentration of calcium or PIP2 [25,26]. While cap
g has not been studied in tumor cells, changes in cell
shape associated with growth, division and migration
are essential events during tumorigenesis and require
the cogent regulation of the cytoskeleton. Like
S100A4 [27,28], S100A11 is associated with cytoskel-
etal elements, and it may function by inhibiting pro-
tein kinase C [29]. S100A11 has not been studied in
tumor cells, but like S100A4 its expression may cor-
relate with malignancy and metastatic disease. As
revealed in the present study, cap g, S100A11 and
S100A6 are expressed in malignant melanomas of
the uvea but not to a signi¢cant extent in normal
uveal melanocytes. Their relationship to malignancy
must be tested further by transfecting sense and anti-
sense constructs into normal uveal melanocytes and
spindle cell and epithelioid cell malignant melanomas
in order to determine whether their altered expres-
sion correlates with changes in the growth and dis-
semination of tumor cells in vitro and in athymic
mice.
The current treatment of uveal melanoma consists
of enucleation and/or radiation exposure, but neither
approach has yet modi¢ed metastatic processes that
Fig. 7. Calcium-binding proteins in a primary ocular tumor. Within 30 min of enucleation, melanoma tumor tissue was dissected and
an extract processed for phenyl-Sepharose chromatography (A) and immunoblotting (B) as described in Section 2 and in the legend
of Fig. 1. Antibodies were speci¢c for: annexin VI (lane a), cap g (b), annexin V (c), calmodulin (d), S100A11 (e), S100B (f) and
S100A6 (g).
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eventually limit life expectancy [30]. It is therefore
relevant to determine whether speci¢c calcium-bind-
ing proteins and the pathways in which they function
may serve as sites for intervention with drug treat-
ment or gene therapy.
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